Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Band 3 anion transport protein, also known as Anion exchanger 1 (AE1) or SLC4A1, is the most abundant integral membrane protein in human erythrocytes, playing a pivotal role in both gas transport and structural integrity [UniProt, 2024]. It functions as a dimeric or tetrameric transporter that facilitates the electroneutral exchange of chloride and bicarbonate ions across the red blood cell membrane, a process essential for the transport of carbon dioxide from tissues to the lungs [Reithmeier et al., 2016]. Beyond its transport function, the large N-terminal cytoplasmic domain of Band 3 serves as a critical anchor, linking the lipid bilayer to the underlying spectrin-based cytoskeleton through interactions with ankyrin, protein 4.2, and protein 4.1 [Lux, 2016]. This Erythrocyte band III – membrane interaction is fundamental to maintaining the mechanical stability and characteristic biconcave shape of erythrocytes, allowing them to survive the high-shear environment of the circulatory system [Gallagher, 2013]. Mutations that disrupt these interactions are the primary cause of hereditary spherocytosis and Southeast Asian ovalocytosis, where the loss of membrane-cytoskeleton cohesion leads to surface area loss and premature splenic clearance [Gallagher, 2013]. Furthermore, Band 3 is a significant factor in malaria pathogenesis, as it is targeted by Plasmodium falciparum for both invasion and the subsequent cytoadherence of infected cells to the vascular endothelium [Zuccala & Baum, 2011]. While currently targeted primarily by research compounds like DIDS to study anion exchange, Band 3 remains a key focus for therapeutic strategies aimed at stabilizing the erythrocyte membrane in hemolytic disorders or blocking parasite entry [Reithmeier et al., 2016; PubChem, 2024].
Inhibition of chloride/bicarbonate exchange or stabilization of the linkage between the plasma membrane and the spectrin-based cytoskeleton.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Band 3 anion transport protein (SLC4A1) (AE1).